Nov 06, 2019
Portola Pharmaceuticals to Present Multiple Abstracts at the 61st American Society of Hematology (ASH) Annual Meeting
Nov 05, 2019
Portola Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Nov 01, 2019
Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Oct 28, 2019
Portola Pharmaceuticals Presents New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Acute Gastrointestinal Bleeding
Sep 19, 2019
Portola Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors
Aug 22, 2019
Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Aug 12, 2019
Portola Pharmaceuticals Announces Proposed Offering of Common Stock
Aug 07, 2019
Portola Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Aug 06, 2019
Portola Launches European Sales of Ondexxya® (Andexanet Alfa) with First Orders in Europe
Aug 05, 2019
U.S. Centers for Medicare and Medicaid Services (CMS) Increases New Technology Add-On Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa
Jul 17, 2019
Portola Pharmaceuticals to Announce Second Quarter 2019 Financial Results on Wednesday, August 7, 2019
Jun 19, 2019
Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma
Apr 27, 2018
Biotech Stocks' Research Reports Released on Pieris Pharma, Portola Pharma, Protalix BioTherapeutics, and Radius Health
Mar 20, 2018
Quotidian Technical Highlights on Selected Biotech Stocks -- Portola Pharma, Protalix BioTherapeutics, Radius Health, and Regulus Therapeutics